CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Sunitinib malate

Last Updated: September 20, 2006
Result type: Reports
Project Number: SR0077-000
Product Line: Reimbursement Review

Generic Name: Sunitinib malate

Brand Name: Sutent

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Cancer, Metastatic renal cell carcinoma

Indications: Cancer, Metastatic renal cell carcinoma

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: April 26, 2007

Recommendation Type: Do not list